First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value

@inproceedings{Wuyts2016FirstDO,
  title={First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value},
  author={Wim Wuyts and Martin Kolb and Susanne Stowasser and Wibke Stansen and John T Huggins and Ganesh Raghu},
  booktitle={Lung},
  year={2016}
}
In the Phase III INPULSIS® trials, 52 weeks’ treatment with nintedanib reduced decline in forced vital capacity (FVC) versus placebo in patients with idiopathic pulmonary fibrosis (IPF). Patients who completed the INPULSIS® trials could receive nintedanib in an open-label extension trial (INPULSIS®-ON). Patients with FVC <50 % predicted were excluded from INPULSIS®, but could participate in INPULSIS®-ON. In patients with baseline FVC ≤50 % and >50 % predicted at the start of INPULSIS®-ON, the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.
16 Citations
17 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

  • L Richeldi, RM du Bois, G Raghu
  • N Engl J Med
  • 2014
Highly Influential
4 Excerpts

results from the INPULSIS trials

  • M Kolb, L Richeldi, IPF Kimura T et al Effect of baseline FVC on decline i with
  • Am J Respir Crit Care Med 191:A1021 Lung
  • 2016

Effect of baseline FVC on lung function decline with nintedanib in patients with IPF

  • TM Maher, KR Flaherty, PW Noble
  • Eur Respir J 46(Suppl
  • 2015

Similar Papers

Loading similar papers…